FDA Pediatric Oncology Advisors Seek Meaningful Trial Plans For Mutually Beneficial Review
This article was originally published in The Pink Sheet Daily
Executive Summary
As the message that pediatric trials may be necessary or required has apparently gotten across to industry, ODAC’s Pediatric Subcommittee is ready to advise developers on trials that might help improve the way pediatric cancer drugs are developed. Nominations are being accepted for its December meeting.